Multimodal artificial intelligence models from baseline histopathology to predict prognosis in HR+ HER2- early breast cancer: Subgroup analysis.

Daniel Kates-Harbeck,Hans Heinrich Kreipe,Oleg Gluz,Matthias Christgen,Sherko Kuemmel,Monika Karla Graeser,Sven Mahner,Doris Mayr,Rachel Wuerstlein,Akinori Mitani,Jingbin Zhang,Hans Pinckaers,Yi Ren,Jessica Keim-Malpass,Jacqueline Griffin,Gijs Smit,Felix Y Feng,Andre Esteva,Ronald E. Kates,Nadia Harbeck
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.101
IF: 45.3
2024-05-31
Journal of Clinical Oncology
Abstract:101 Background: Prognostic assessment in HR+ HER2- early breast cancer (EBC) remains challenging given relatively low rates of disease progression. Modern artificial intelligence (AI)-based techniques have already provided substantial medical progress, particularly in prostate cancer. We have leveraged ArteraAI’s multimodal artificial intelligence (MMAI) platform to develop a research-level prognostic model in HR+ HER2- EBC, based on the WSG PlanB and ADAPT trials. Here, we quantify the value added by MMAI within clinically relevant subgroups. Methods: Histopathology image data was generated from pre-treatment breast biopsy and surgical hematoxylin and eosin (H&E) slides from the WSG PlanB and ADAPT trials. Patients with available images and complete data (n=5259) were allocated (stratified by trial, randomization arm and distant recurrence (DR)) to development (60%) and validation (40%) cohorts. An MMAI-based model using image data combined with clinical prognostic variables (age, T and N stage, tumor size) was developed to predict risk of DR. Univariable and multivariable Fine-Gray models were used to assess performance in the validation cohorts; subdistribution hazard ratios (sHR) refer to validation cohorts and are reported per standard deviation increase of the model scores (image-alone or combined). Pre-specified prognostic subgroups for analysis were defined by nodal status, menopausal status, and central tumor grade. All statistical tests were 2-sided at .05 significance. Results: The trained MMAI score was significantly associated with risk of DR in the validation cohort (sHR [95% CI] = 2.3 [2.0-2.8]) as a whole and in all considered subgroups. The score remained significant (sHR [95%CI] = 2.2 [1.7-2.8]) after adjusting for clinical prognostic factors. Moreover, the MMAI image component alone had significant prognostic value (sHR [95%CI] = 1.6 [1.3 - 1.9]) in the validation cohort. Remarkably, the MMAI image component alone had significant prognostic value separately within the G2 and G3 sub-groups, with sHR of about 1.5 per standard deviation increase, and also in most of the other predefined clinical subgroups. Conclusions: Preliminary results from the current MMAI breast model provide evidence that ArteraAI MMAI technology can be leveraged for outcome prediction in HR+ HER2- EBC using H&E-stained images to further personalize breast cancer management. The ability of image-only AI models to provide significant prognostic value within grade subgroups suggests that self-supervised AI has identified some novel image features with prognostic value beyond grade. To put the results into the clinical context, comprehensive validation analyses will be presented at the meeting.
oncology
What problem does this paper attempt to address?